NEW YORK (GenomeWeb News) – Invitrogen said today it will continue to screen kinase inhibitors for Chroma Therapeutics after the companies extended an earlier agreement.
 
Invitrogen will use its SelectScreen service at its facility in Paisley, Scotland, to screen targets, study phylogenetic diversity, and explore signaling pathways to help Chroma Therapeutics “rapidly confirm the selectivity and potency of our small-molecule drugs,” Chroma Therapeutics CSO Alan Drummond said in a statement.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.